



Antengene to Attend Evercore 2nd China Biotech Summit and Participate in a Fireside Chat

Shanghai and Hong Kong, PRC, August 11, 2026 -- Antengene Corporation Limited ("**Antengene**", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, today announced that **it will attend the Evercore 2nd China Biotech Summit, to be held from August 17th to 19th at the Ritz-Carlton Shanghai, Pudong. During the event, Antengene will provide an update on its R&D progress as well as its strategic initiatives in a featured fireside chat.**

The summit, organized and hosted by Evercore ISI, a world-leading independent investment banking advisory firm, will bring together biotech industry leaders, top analysts, as well as investors from Europe and the U.S. to discuss the latest trends and investment opportunities in the biopharmaceutical sector. The event serves as an important platform connecting China's innovative drug companies with global investors.



Fireside Chat

Time: August 18, 2026, Tuesday, 10:30-10:45 Beijing Time

Venue: Grand Ballroom 2 & 3, The Ritz-Carlton Shanghai, Pudong

Management Attendees:

Dr. Bing Hou, Chief Scientific Officer

Ms. Ariel Guo, Chief Business Officer

Corporate Meeting Reservations

Date: August 17th to 19th, 2026

Antengene's management team will be available for corporate meetings and discussions during the conference. **Interested parties are welcome to contact Antengene's Business Development / Investor Relations team to arrange a meeting.** We look forward to engaging in meaningful discussions, exploring new partnership opportunities across the healthcare sector, and working together to accelerate innovation and industry growth.

About Antengene

Antengene Corporation Limited ("**Antengene**" , SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on



developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 x PD-L1 bispecific ADC), ATG-207 (α CD3-TGF- β bifunctional fusion protein), as well as T cell engager (TCE) programs developed using Antengene's proprietary AnTenGager[®] platform.

AnTenGager[®] is Antengene's proprietary TCE 2.0 platform, featuring "2+1" bivalent binding for low expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune disease, solid tumors and hematological malignancies, with programs targeting CD19 x CD3 (ATG-201 for B cell-related autoimmune diseases; partnered with UCB), CDH6 x CD3 (ATG-106 for ovarian cancer and kidney cancer; partnered with K2 Therapeutics established by MPM BioImpact), ALPPL2 x CD3 (ATG-112 for gynecological tumors, digestive system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal



cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102 for acute myeloid leukemia and chronic myelomonocytic leukemia) and FLT3 x CD3 (ATG-107 for acute myeloid leukemia).

To date, Antengene has obtained 33 investigational new drug (IND) approvals in the U.S. and Asia, and obtained new drug application (NDA) approvals in 10 Asia Pacific markets. Its lead commercial asset, XPOVIO® (selinexor), is approved in the Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland of China, Taiwan China, Australia, South Korea and Singapore).

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with

the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2025, and the documents subsequently submitted to the Hong Kong Stock Exchange.